New
Incyte wins EU nod for vitiligo cream Opzelura
Great news for the vitiligo community in the EU!
Incyte has just announced in a press-release that ruxolitinib cream (Opzelura™) has received a positive opinion from the European Medicines Agency (EMA) committee for the treatment of vitiligo with facial involvement.
The green light opens the fast track way for it to become the first ‘official’ vitiligo therapy available in the EU. Incyte has been eagerly awaiting approval in the EU ever since the it’s drug was registered by the US FDA in July 2022.
Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.
FAQOther Questions
- Diabetes and Vitiligo: Is There a Connection?
Yes, there appears to be a real connection between vitiligo and diabetes, especially type 1 diabetes. A recent study using UK Biobank data also found an association with type 2 ...
- What causes vitiligo?
The exact cause is a complex puzzle, but we know the foundation: It is pre-wired in your genes. Think of your genetics as a loaded spring, just waiting for a specific "trigger" ...
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.